Clinical Trial Update: A Study of LY2940094 in Major Depressive Disorder [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating LY2940094 for Major Depressive Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• LY2940094

Snippet

Sponsor: BlackThorn Therapeutics, Inc. | Conditions: Major Depressive Disorder | Phase 1 | Status: COMPLETED